Scarica l'app Stockscreener
41.49
1.59%
-0.67
Pre-mercato:
42.31
0.82
+1.98%
Precedente Chiudi:
$42.16
Aprire:
$42.34
Volume 24 ore:
455.57K
Relative Volume:
1.05
Capitalizzazione di mercato:
$1.80B
Reddito:
$384.10M
Utile/perdita netta:
$-9.07M
Rapporto P/E:
-296.36
EPS:
-0.14
Flusso di cassa netto:
$11.10M
1 W Prestazione:
+2.98%
1M Prestazione:
+6.41%
6M Prestazione:
+55.39%
1 anno Prestazione:
+95.62%
Intervallo 1D:
$41.38
$42.93
Intervallo di 1 settimana:
$39.61
$42.93
Portata 52W:
$17.82
$42.93
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Nome
Kiniksa Pharmaceuticals International Plc
Settore
Telefono
(781) 431-9100
Indirizzo
23 OLD BOND STREET, FLOOR 3, LONDON
Confronta KNSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
41.49 | 3.20B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-29 | Iniziato | TD Cowen | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2024-05-03 | Iniziato | Wells Fargo | Overweight |
| 2020-06-29 | Reiterato | BofA Securities | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-12-12 | Reiterato | Wedbush | Outperform |
| 2018-06-19 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Kiniksa Pharmaceuticals International Plc Borsa (KNSA) Ultime notizie
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 12,470 Shares of Stock - MarketBeat
SG Americas Securities LLC Acquires 127,126 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharma COO Tessari sells shares worth $514,224 - Investing.com India
Kiniksa Pharma COO Tessari sells shares worth $514,224 By Investing.com - Investing.com UK
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week HighTime to Buy? - MarketBeat
Los Angeles Capital Management LLC Sells 36,570 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Savant Capital LLC Invests $398,000 in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Mark Ragosa Sells 19,900 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Rides ARCALYST Growth To Outpace The S&P 500 - Finimize
Exploring High Growth Tech Stocks in the US Market - Yahoo Finance
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London - The Manila Times
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Increases 5.3% This Week, Taking Five-year Gains to 166% - 富途牛牛
Kiniksa (NASDAQ: KNSA) to present at Jefferies Healthcare Conf.; live webcast Nov. 17 - Stock Titan
Connor Clark & Lunn Investment Management Ltd. Has $17.26 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Acquired by Acadian Asset Management LLC - MarketBeat
Fox Run Management L.L.C. Buys 24,391 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Vanguard Group Inc Reduces Stake in Kiniksa Pharmaceuticals Inte - GuruFocus
John Paolini Sells 82,542 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates - MSN
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Kiniksa Pharmaceuticals CMO Sells Shares - TradingView
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2025 Earnings Call Transcript - Insider Monkey
Y Intercept Hong Kong Ltd Buys New Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Asset Management One Co. Ltd. Boosts Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Equities Analysts Offer Predictions for KNSA FY2025 Earnings - MarketBeat
Kiniksa raises 2025 ARCALYST sales guidance to $670M-$675M as market penetration grows - MSN
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock By Investing.com - Investing.com Australia
Ragosa Mark, CFO of Kiniksa, sells $4100 in KNSA stock - Investing.com
[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity - Stock Titan
New Strong Sell Stocks for Oct. 30th - The Globe and Mail
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage - Seeking Alpha
Goldman Sachs Raises Target Price for Kiniksa Pharmaceuticals (K - GuruFocus
Kiniksa Ramps Up Revenue Forecast As ARCALYST Gains Traction - Finimize
Kiniksa Pharmaceuticals International’s (KNSA) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Kiniksa Pharmaceuticals (KNSA): Assessing Valuation After Strong ARCALYST Growth, Raised Guidance, and FDA Orphan Drug Win - Yahoo! Finance UK
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Kiniksa Pharmaceuticals International, plc SEC 10-Q Report - TradingView
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighHere's Why - MarketBeat
Key Developments in KNSA Revenue Forecasts - GuruFocus
Q3 2025 Earnings Call - MarketScreener
KNSA Surpasses Revenue Expectations and Updates Sales Forecast - GuruFocus
Kiniksa Pharmaceuticals Swings to Q3 Net Income, Revenue Increases - MarketScreener
Kiniksa Pharmaceuticals Q3 2025 Earnings: Revenue Surpasses Esti - GuruFocus
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q3 EPS $0.23, vs. FactSet Est of $0.32 - MarketScreener
Kiniksa Pharmaceuticals International Plc Azioni (KNSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.17%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):